Founder, Chief Executive Officer
Founder and CEO of Lysogene, Ms. Aiach is also the mother of a child with MPS IIIA. She has a strong business background starting her career with Arthur Andersen specializing in audit and transaction services. Her entrepreneurial experience includes founding and running a financial business consultancy. From 2008 to 2009, Ms. Aiach served as a Member of the Pediatric Committee at the European Medicines Agency (EMA), established in accordance with the European Pediatric Regulation, as a patient representative. In 2008, she also served on the French Ethical Review Board CCPPRB at Ambroise Paré Hospital. Ms. Aiach has been involved with several not-for-profit organizations engaged in advocacy and research in the field of rare diseases such as Alliance Sanfilippo and Eurordis, where she served on the board as treasurer from 2010 to 2011. She is a founding executive member of the International Rare Diseases Research Consortium (IRDiRC).
Ms. Aiach graduated from the ESSEC Business School and majored in Economics.
Chief Scientific Officer
Kim is responsible for the continuing development of Lysogene’s scientific programmes. Prior to joining Lysogene, Kim was Senior Vice President of Preclinical Research and Development at NeuroPhage Pharmaceuticals, Inc., where she directed preclinical and nonclinical drug development activities. She has also held various leadership positions at several early stage ventures, including CereMedix where she was VP of Research & Development, EPIX (Predix) Pharmaceuticals where she served as Senior Director of Biology, and Eolas Biosciences where she was Head of US Operations.
Dr. Gannon received her PhD in Neuroscience from Florida State University and conducted her postdoctoral training at the Roche Institute of Molecular Biology, Hoffmann-LaRoche Inc., in New Jersey and at Mount Sinai School of Medicine in the Department of Physiology and Biophysics in New York.
Chief Technical Officer
Mark is responsible for Lysogene’ s manufacturing strategy and CMC operational development. He has extensive technical experience across a diverse range of functions, proven knowledge of quality compliance and regulatory requirements and strong business and leadership skills gained from over 30 years of experience working in North America, Europe and Australasia. Prior to joining Lysogene, Mark worked as Head of Process Development and Manufacturing at Torque Therapeutics, leading multiple functions including process and analytics development and ensuring quality controls and design across manufacturing. Prior to that, Dr. Plavsic held multiple positions with Sanofi Genzyme, Astra Zeneca and Invitrogen Corporation.
Dr. Plavsic received his Ph.D in Virology and Molecular Cell Biology, M.S. in Virology and Immunology, and Doctor of Veterinary Medicine degree from the University of Belgrade in Yugoslavia. He has a Board certification in Microbiology, subspecialty Virology from the American College of Veterinary Microbiologists.
Senior Vice President and Chief Medical Officer
Soraya is responsible for Lysogene’s clinical development and regulatory affairs. Physician by background, Soraya specialized in clinical research and biostatistics before starting her career in academia. Prior to joining Lysogene, Soraya worked for Aventis Pharma, followed by Orphan Europe, a pharmaceutical company dedicated to the development of treatments for rare diseases, before joining Sanofi in 2007, where she held successively increasing leadership positions including Vice President and Global Ophthalmology Unit Head.
Soraya’s extensive industry experience spanning from early development to ensuring market access, with an important focus on viral and non-viral gene therapy products, has led to a rich breadth of experience across a variety of therapeutic areas.
Chief Patient Access Officer
Samantha Parker is Head of Lysogene’s Patient and Policy Affairs. Ms. Parker has specialised in rare disease research and public health since 2000. She has focused on expanding the expert disease community of healthcare professionals, patients, industry and regulators; building disease registries and natural history studies; developing consensus care guidelines; and developing strategies to improve the quality of diagnosis and patient care. Ms. Parker contributed, for several years, to the area of independent professional education in rare diseases. She is a member of the European Group of Experts on Rare Diseases (EGRD) and the International Rare Diseases Research Consortium (IRDiRC).
Ms. Parker has a B.A. (Hons) from Edinburgh University and an M.B.A (with distinction) in Life Sciences.
Vice President of Regulatory Affairs and Quality Assurance
Sean is responsible for providing global regulatory strategic leadership and for the creation and maintenance of quality systems assuring global compliance. Prior to joining Lysogene, he was the Director of Regulatory Affairs at bluebird bio leading efforts on the treatment of the rare disease CCALD through LVV gene therapy where he initiated and led the RA CMC group across all programs including CNS, hematology and oncology. Prior to this, he worked 8 years at Genzyme/Sanofi serving as a global regulatory lead for the Cell Therapy and Regenerative Medicine division. Sean has more than 20 years of regulatory experience across a range of categories including biologics, gene therapy, chemistry, manufacturing and control (CMC) and medical device
Sean holds a BS in Biology and Analysis and Policy from Boston University and is RAPs certified.
Sarah is responsible for overseeing Lysogene’s financial operations, budget and financing strategy. Prior to joining Lysogene, she was CFO at Theraclion where she successfully led the company’s IPO in 2014. She acquired her financial knowledge related to Bio- and Medtech companies, including fundraising (Europe and USA) during the six years she spent at Ernst & Young working on legal audit and advisory/acquisition missions in the healthcare sector.
Sarah is a graduate of the National Institute of Agronomy (INA P-G/AgroParisTech) and has a Masters in Economy and Management.